➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts

Last Updated: January 16, 2021

DrugPatentWatch Database Preview

Details for Patent: 6,335,447

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,335,447 protect, and when does it expire?

Patent 6,335,447 protects XEPI and is included in one NDA.

This patent has thirteen patent family members in twelve countries.

Summary for Patent: 6,335,447
Title: Quinolonecarboxylic acid derivatives or salts thereof
Abstract:Novel quinolonecarboxylic acid derivatives of general formula (1) or salts thereof which have potent antibacterial effects on gram-positive bacteria in particular Propionibacterium acnes ##STR1## (wherein R.sup.1 represents a hydrogen atom or a carboxyl-protective group; R.sup.2 represents an optionally substituted cycloalkyl group; R.sup.3 represents a hydrogen atom, a halogen atom, an optionally substituted alkyl, alkoxy or alkylthio group, an optionally protected hydroxyl or amino group, or a nitro group; R.sup.4 represents an optionally substituted alkyl or alkoxy group; and Z represents a pyridin-4-yl or pyridin-3-yl group which is optionally substituted with at least one group selected from a halogen atom, an optionally substituted alkyl, alkenyl, cycloalkyl, alkoxy, alkylthio or amino group and an optionally protected hydroxyl or amino group).
Inventor(s): Hayashi; Kazuya (Toyama, JP), Kito; Tokunori (Toyama, JP), Mitsuyama; Junichi (Toyama, JP), Yamakawa; Tetsumi (Toyama, JP), Kuroda; Hiroshi (Ishikawa, JP), Kawafuchi; Hiroyo (Toyama, JP)
Assignee: Toyama Chemical Co., Ltd. (Tokyo, JP)
Application Number:09/647,763
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 6,335,447

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ferrer Internacional XEPI ozenoxacin CREAM;TOPICAL 208945-001 Dec 11, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,335,447

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan10-110146Apr 6, 1998
Japan10-340217Nov 30, 1998
PCT Information
PCT FiledApril 06, 1999PCT Application Number:PCT/JP99/01799
PCT Publication Date:October 14, 1999PCT Publication Number: WO99/51588

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.